Title: Hodge RJ, et al. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22.
1203494-49-8
1365836-50-5
1082556-61-3
1538453-90-5
447410-61-9
937618-33-2
380426-71-1 | 2-Chloro-5-[3-(2-oxo-pyrrolidin-1-yl)-propylsulfamoyl]-benzoic acid | AA019GKE | MFCD03150433
565194-83-4 | 2-chloro-N-[2-methoxy-5-(morpholine-4-sulfonyl)phenyl]acetamide | AA019GUU | MFCD03970376
926205-33-6 | 5-Amino-2-phenyl-4-(4,5,6,7-tetrahydro-3h-azepin-2-yl)-2h-pyrazol-3-ol | AA019H2P | MFCD06660615
313069-92-0 | 1-(2-chloro-5-nitrophenyl)-2,5-dihydro-1H-pyrrole-2,5-dione | AA019HIR | MFCD02084276
1093344-89-8 | (5Z)-3-(2-aminoethyl)-5-[(4-methylphenyl)methylidene]-1,3-thiazolidine-2,4-dione hydrochloride | AA019HSR | MFCD08445272
571149-70-7 | 3-(2-chloroacetyl)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)urea | AA019I2C | MFCD03980932
40160-35-8 | Sodium 3-(4-chloro-phenyl)-3-oxo-propen-1-olate | AA019IDS | MFCD04621494
796067-64-6 | 4-Chloro-2-pyridin-3-yl-6,7-dihydro-5h-cyclopenta[4,5]thieno[2,3-d]pyrimidine | AA019INM | MFCD06370794
560998-03-0 | 4-Amino-5-(2-methyl-3-furyl)-4H-1,2,4-triazole-3-thiol | AA019IYP | MFCD04608597
1049751-46-3 | 2-(Sec-butylamino)-n-[2-(trifluoromethyl)phenyl]acetamide hydrochloride | AA019J9I | MFCD07287154